Nasdaq-listed Impax Laboratories Inc. (IPXL) has appointed premier investment bank Morgan ... 9% to hit intraday high of $9.50 per share during Tuesday afternoon. The stock is currently up by over 3%. (See also: Market Vectors Launches …
Though recent challenges with its manufacturing facility in Hayward, CA involving an FDA Warning Letter & multiple …
A month has gone by since the last earnings report for Impax Laboratories, Inc. IPXL. Shares have added about 35.3% in that time frame, outperforming the market. Will the recent positive trend continue leading up to the stock's next …
One such stock that you may want to consider dropping is Impax Laboratories Inc. IPXL, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current …
Impax Laboratories Inc. (NASDAQ: IPXL) dropped about 28% on Tuesday to post a new 52-week low of $22.08 after closing at $30.59 on Monday. The stock’s 52-week high is $47.48. Volume reached nearly 10 times the daily average of …
Impax Laboratories Inc. (IPXL) Gained 10.44% to close Thursday's trading at $ ... News: The Company launched a follow-on public offering of $225 million of shares of its common stock. In addition, Juno expects to grant the underwriters a 30 …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IPXL at https://www.zacks.com/ap/IPXL Keywords: Impax Laboratories, …
That is because a stock needs to have both a positive Earnings ESP and a ... Story Continues The Earnings ESP for Impax Laboratories Inc. IPXL is +3.03%. The Earnings ESP for Ionis Pharmaceuticals, Inc. IONS is +38.00%. Incyte …
Inded, Impax Laboratories’ stock traded as high as $27.02 per share on October 2, 2012 and declined to as low as …